Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage

Background: We recently demonstrated that recombinant activated factor VII (rFVIIa) given to patients presenting within 3 h of acute spontaneous intracerebral hemorrhage (ICH) reduces mortality (18% vs. 29%) and poor outcome (modified Rankin Scale, mRS, 4 - 6, 53 vs. 69%). This analysis was performed to determine the impact of rFVIIa on health-related quality of life (HRQoL) in those patients. Methods: In a prospective, randomized controlled trial, 399 patients ( mean age, 66 years) received placebo, 40, 80 or 160 mu g/kg of rFVIIa within 4 h of acute ICH. At 90 days, HRQoL was assessed with the EuroQoL (EQ-5D), a 5-dimensional measure of health which also includes the Visual Analogue Scale. Additionally, each level of the 90-day mRS was adjusted, using 4 different previously published utility values, to obtain a clearer picture of perceived HRQoL. Results: Among the 5 dimensions of EQ-5D, only mobility rating was significantly better for rFVIIa-treated patients ( serious problems, 34 vs. 54%; p = 0.01). Yet, the utility value ( scaled 1.0 = perfect health and 0.0 = dead) associated with the composite EQ-5D demonstrated significantly better HRQoL (0.48 vs. 0.36; p = 0.01). This was also true for the EQ-5D Visual Analogue Scale score ( 44 vs. 36; p = 0.04). Finally, all 4 algorithms for applying utility scores to the mRS indicated that rFVIIa was associated with significantly better perceived HRQoL ( all p ! 0.006). Conclusions: Treatment with rFVIIa within 4 h of acute spontaneous ICH improves HRQoL. Copyright (c) 2007 S. Karger AG, Basel.